<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191280</url>
  </required_header>
  <id_info>
    <org_study_id>1138.2</org_study_id>
    <nct_id>NCT02191280</nct_id>
  </id_info>
  <brief_title>Antistax® in Patients With Chronic Venous Insufficiency</brief_title>
  <official_title>The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the efficacy and tolerability of two dose levels of Antistax relative to
      placebo in patients suffering from CVI grade I or incipient grade II
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">September 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of limb volume</measure>
    <time_frame>Baseline, day 84</time_frame>
    <description>determined by water displacement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of limb volume</measure>
    <time_frame>Baseline, days 42 and 98</time_frame>
    <description>determined by water displacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of calf circumference</measure>
    <time_frame>Baseline, days 42, 84 and 98</time_frame>
    <description>in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of ankle circumference</measure>
    <time_frame>Baseline, days 42, 84 and 98</time_frame>
    <description>in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjective symptoms on a visual analogue scale (VAS)</measure>
    <time_frame>Baseline, days 42, 84 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global efficacy by patient on a 4-point verbal rating scale</measure>
    <time_frame>days 42, 84 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global efficacy by investigator on a 4-point verbal rating scale</measure>
    <time_frame>days 42, 84 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global tolerability by patient on a 4-point verbal rating scale</measure>
    <time_frame>days 42, 84 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global tolerability by investigator on a 4-point verbal rating scale</measure>
    <time_frame>days 42, 84 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Antistax®, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antistax®, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antistax®, low dose</intervention_name>
    <arm_group_label>Antistax®, low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antistax®, high dose</intervention_name>
    <arm_group_label>Antistax®, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Between 25 and 75 years of age

          -  CVI I or CVI II (without expanded trophic disturbances)

          -  Willing and able to give written informed consent prior to participation in the study

        Exclusion Criteria:

        Concomitant disease(s) exclusion criteria:

          -  Decompensated cardiac insufficiency

          -  Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal
             insufficiency, lymph edema, etc)

          -  Peripheral arterial disease (ankle/arm pressure index &lt; 0.9)

          -  Current acute phlebitis or thrombosis

          -  Renal insufficiency (Serum creatinine &gt; 1.5 mg/dl)

          -  Liver disease (SGPT (ALAT) &gt; 3x upper limit of normal)

          -  Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or
             hypocalcaemia, malignancies

          -  Anamnestic indications of diabetic microangiopathy or polyneuropathy

          -  Drug and/or alcohol abuse

          -  Severe climacteric complaints

          -  Immobility

          -  Avalvulia

          -  Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus,
             Haemangiectasia hypertrophicans)

          -  State after pulmonary embolism

          -  Recognized hypersensitivity to the trial drug ingredients

          -  Current florid venous ulcus

          -  Clinical indication for a necessary, specific phlebologic acute treatment, e.g.
             compressive treatment, phlebectomy, etc.

        Previous treatment(s) exclusion criteria:

          -  Treatment with venous drugs within the last 4 weeks

          -  Treatment with laxatives which affect fluid or electrolyte balance within the last 8
             days

          -  Changes in or unstable response to treatment with theophylline, diuretics, cardiac
             glycosides, ACE inhibitors or calcium antagonists within the last 8 days

          -  Changes in post-menopausal Hormone replacement within the last 2 months

        Concomitant treatment/non-drug therapy exclusion criteria:

          -  Other venous drugs apart from the trial medication

          -  Compression therapy

          -  Venous surgery at the leg(s)

          -  Extensive use (on more than a total of 6 days during the entire trial) of laxatives
             which affect fluid or electrolyte balance

          -  Major surgery requiring full anesthesia

        Other exclusion criteria:

          -  Previously studied under this protocol

          -  Participation in another clinical trial within the previous 90 days or during the
             present study

          -  Patients who have visited a sauna or had other thermal applications in the previous
             day before any visit

          -  Pregnant or nursing women or inadequate birth control methods (this applies to females
             of childbearing potential only)

          -  Patients considered as mentally ill as well as unable to work or with limited working
             ability, or unable (or only partially able) to follow the spoken or written
             explanations concerning the trial

          -  Patients in a bad general health state according to the investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

